Test directory: HLA-B27

Ordering Code458
Test NameHLA-B27
AliasB27
Preferred SpecimenWhole Blood
Preferred ContainerSodium Heparin (Green)
Other Specimen/ContainerWhole Blood in ACD-B (Yellow),
Whole Blood in EDTA, K2 (Lavender),
Whole Blood in Sodium Heparin (Green)
Optimum Volume6 mL
Collection InstructionsDraw full tube
Mix tube(s) well.
Handling InstructionsDo NOT refrigerate or freeze
Do NOT centrifuge specimen
For optimal results, deliver to testing laboratory within 24 hours of collection.
Transport RequirementsOahu: Ambient
Airline: Ambient
Specimen StabilityNa Heparin or ACD: 72 Hours (For optimal results: 24 hours ambient for all specimen types)
Rejection CriteriaClotted, Refrigerated or Frozen
Avail. StatNO
Analytic TimeUp to 3 Days
MethodologyFlow Cytometry
Reference Lab Hawaii Pathologist Laboratory

Reference range(s)

The reference ranges listed below are valid on this date of November 21, 2024.
ComponentAgeMale NormMale Critical LowMale Critical HighFemale NormFemale Critical HighFemale Critical LowUnitsAdd'l info
HLA-B27ALL

HLA-B27...
HLA-B27 antigen is present in 8% of Caucasians, 1-3% of
Asians and 3% of African Americans. In patients with ankylosing spondylitis, HLA-B27 is found in 89%, 85% and 58% of Caucasians, Asians and African Americans, respectively
HLA-B27 is found in 80% of Caucasians with Reiter's disease and 25% of juvenile rheumatoid arthritis patients

Flow cytometric evaluation of HLA-B27 is a screening tool and should be verified with a second method (microcytotoxicity or molecular method) to confirm positive or equivocal results

Test performed by the Queen's Medical Center, Pathology Department

See report.
Note1

Note1:


HLA-B27 antigen is present in 8% of Caucasians, 1-3% of
Asians and 3% of African Americans. In patients with ankylosing spondylitis, HLA-B27 is found in 89%, 85% and 58% of Caucasians, Asians and African Americans, respectively
HLA-B27 is found in 80% of Caucasians with Reiter's disease and 25% of juvenile rheumatoid arthritis patients

Flow cytometric evaluation of HLA-B27 is a screening tool and should be verified with a second method (microcytotoxicity or molecular method) to confirm positive or equivocal results

Test performed by the Queen's Medical Center, Pathology Department

See report..